SCN2A Gene Test for Benign Familial Infantile Convulsions (BFIC3) in UAE – 2800 AED

Executive Summary & Core Metrics

Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited NGS Processing.
Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Daily 8 AM – 11 PM).
Clinical Guidance: Telephonic Post-Test Clinical Guidance from a Consultant Medical Genetics.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.

Test Overview & Methodology

This advanced next-generation sequencing (NGS) test analyzes the entire coding region and splice sites of the SCN2A gene for pathogenic variants linked to benign familial infantile convulsions type 3 (BFIC3), a self-limited epilepsy syndrome presenting in early infancy. The test offers superior diagnostic accuracy compared to single-exon Sanger sequencing.

Feature	Our Test (NGS Full Gene Analysis)	Closest Alternative (Sanger Single‑Exon)
Methodology	Next‑Generation Sequencing (NGS)	Sanger Sequencing
Diagnostic Sensitivity	99.9% (coding + splice sites)	~85% (hotspot only)
Turnaround Time	3–4 Weeks	6–8 Weeks (for full gene walk)

Physician Insight & Safety Protocols

“As a Consultant Medical Genetics, I emphasize that a positive SCN2A result must be interpreted alongside the child’s clinical and family history, as well as EEG findings. We ensure compassionate communication and guide families through next steps. Please note that this genetic test does not replace ongoing medical care and regular follow-ups with your pediatric neurologist.” – Lina Osama Zaki Quteineh, DHA Registration ID: 9294403

Medication Advisory

⚠️ Do not discontinue prescribed anti‑epileptic medication without consulting your doctor. Abrupt withdrawal may trigger severe seizure exacerbation.

Exclusion Criteria & Emergency Red Flags

Patients with uncorrected bleeding diathesis or inability to provide adequate venous access.
Minors without a legal guardian’s consent as per Federal Decree-Law No. 4 of 2016 on Medical Liability.
Individuals who have not received mandatory pre‑test genetic counselling.

🚨 Seek immediate emergency care if your child develops:

Prolonged seizure lasting more than 5 minutes (status epilepticus).
Difficulty breathing, cyanosis, or loss of consciousness.
New focal neurological deficits or altered mental status.

Patient FAQ & Clinical Guidance

1. What is the SCN2A gene test and who should consider it?

Snippet‑Worthy Answer: The SCN2A gene test sequences the entire SCN2A gene to identify mutations causing benign familial infantile convulsions (BFIC3), recommended for infants with recurrent afebrile seizures or a positive family history.

2. How is the sample collected and what is the process?

Snippet‑Worthy Answer: A small sample of blood, extracted DNA, or a drop of blood on an FTA card is collected via our VIP mobile phlebotomy service, then transported under ISO‑certified cold‑chain logistics. Home collection is available daily from 8 AM to 11 PM.

3. When will I receive my results and how to interpret them?

Snippet‑Worthy Answer: Results are released within 3–4 weeks and include a comprehensive clinical interpretation; a complimentary tele‑counselling session with a Consultant Medical Genetics is provided immediately after.

UAE Regulatory & Data Privacy Adherence

All genetic testing and data handling at DNA Labs UAE strictly comply with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient consent is obtained in accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability. Your genetic data remains confidential and is only used for diagnostic purposes.

Clinical & Logistical Metadata

Test Name	SCN2A Gene Test (BFIC3)
Price (AED)	2,800
Turnaround Time	3–4 Weeks
Sample Type / Matrix	Whole Blood (Peripheral) or Extracted DNA
Methodology Used	Next-Generation Sequencing (NGS) – Full Gene Coding Region Analysis
ICD-10-CM Code	G40.3
LOINC Code	74774-9
DHA Facility License & Address	License No. 1143 • Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE